Nikhil Pandey

7

Dr. Nikhil Pande

MBBS, MD, DM (Medical Oncology)

appoint

  • MBBS from Terna Medical College, Mumbai in 2009
  • MD (General Medicine) from Kasturba Medical College, Manipal  in 2013
  • DM (Medical Oncology) from Tata Memorial Hospital, Mumbai in 2017
  • Internship at Terna Medical College, New Delhi from January 2008 to January 2009
  • Post Graduate Residency in General Medicine at Kasturba Medical College, Manipal from May 2010 to May 2013
  • Senior Residency at Kasturba Medical College Hospital, Manipal from May 2013 to December 2013
  • Super Specialty training in Medical Oncology from August 2014 to August 2017
  • Specialty Registrar, Medical Oncology from August 2017 till date
  • Haemolytic anaemia–PNH type II cells presenting a diagnostic dilemma. BMJ Case Rep. 2014 Jun. Pande N, Bhat R, Singh BM, Vivek G.
    Simultaneous occurrence of internal capsule infarct and cerebellarhaemorrhage in a patient with hemiplegia.BMJ Case Rep. 2014 Jan.
 Pande N, Vivek G, Hande M, Acharya V
  • Isolated bilateral upper lobar anomalous pulmonary venous connection–a rare anomaly confirmed on CT imaging. BMJ Case Rep. 2012 May. Gupta MK, Shetty R, Pande N, Shenoy P
  • Second-Line Palliative Chemotherapy in Advanced Gall Bladder Cancer, CAP-IRI: Safe and Effective Option. J Gastrointest Cancer. 2016 May 23. [Epub ahead of print]. Ramaswamy A, Ostwal V, Pande N, Sahu A, Jandyal S, Ramadwar M, Shetty N, Patkar S, Goel M, Gupta S.
  • Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K.ESMO Open. 2017 Apr 27;2(1):e000168. doi: 10.1136/esmoopen-2017-000168. eCollection 2017.
  • Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers.Chougule A, Patil VM, Noronha V, Joshi A, Turkkar S, Chandrasekharan A, Pande N, Bagayatkar P, Prabhash K.Oral Oncol. 2017 Jul;70:73-74. doi: 10.1016/j.oraloncology.2017.05.006. Epub 2017 May 22. No abstract available. PMID:28545992
  • Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious.Ramaswamy A, Pande N, Shetty O, Shetty N, Gupta S, Ostwal V.J Gastrointest Oncol. 2016 Aug;7(4):638-43. doi: 10.21037/jgo.2016.03.06.PMID:27563456
  • Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy. Vanita Noronha, Vijay Patil, Amit Joshi, Anuradha Chougule, Atanu Bhattacharjee, Rajiv Kumar, Sucheta More, Supriya Goud, Ashay Karpe, Anant Ramaswamy, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash. Ecancermedicalscience. 2017; 11: 776. Published online 2017 Oct 24. doi: 10.3332/ecancer.2017.776
  • Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation? Amit Joshi, Vanita Noronha, Vijay M. Patil, Anuradha Chougule, Atanu Bhattacharjee, Rajiv Kumar, Supriya Goud, Sucheta More, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Alok Goel, Vikas Talreja, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash. Chemother Res Pract. 2017; 2017: 8196434. Published online 2017 Oct 23. doi: 10.1155/2017/8196434.
  • Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer. Vanita Noronha, Amit Joshi, Vijay Maruti Patil, Jaiprakash Agarwal, Sarbani Ghosh Laskar, Ashwini Narsingrao Budrukkar, Vedang Murthy, Tejpal Gupta, Anil D’Cruz, P. S. Pai, Pankaj Chaturvedi, Devendra Chaukar, Nikhil Pande, et al. DOI: 10.1200/JCO.2017.74.9457 Journal of Clinical Oncology – published online before print December 8, 2017
  • KAPICON 2011- Poster Presentation
  • KAPICON 2012- Poster Presentation
  • APICON 2013 – Poster Presentation
  • ISMPO 2015 – Selected for Oral presentation and won ESMO Asia Singapore travel grant
  • ISMPO 2016 –  Selected for Oral presentation and won ESMO Asia Singapore travel grant
  • Indian Society of Neuro-Oncology Conference 2017- Best Poster Presentation Award
  • Lung Cancer Consortium Asia 2017 – Best Poster Presentation Award
  • Lung Cancer Consortium Asia 2017 – Best Trial in Progress Award
  • IASLC 2016, Vienna- Poster Presentation
  • Mumbai Hematology Group 2017- Oral Presentation
  • IASGO 2016, Seoul – Poster presentation
  • Indian Society of Medical and Paediatric Oncology (ISMPO)
  • American Society of Clinical Oncology (ASCO)